Top Five CRO Signs Agreement with NewCardio
A top five CRO has signed a Master Services Agreement (MSA) with NewCardio, reports the Santa Clara, CA-based cardiac diagnostic and services company. The agreement gives the unspecified CRO a license to use NewCardio's QTinno software, which, according to the company's Web site, "provides fully automated and comprehensive analysis of QT intervals and other ECG markers for cardiac safety assessment in drug development."
"The adoption of QTinno by the clinical pharmacology units at this top five CRO will enable them to deliver quality TQT/QT studies with higher accuracy and lower intrinsic variability in a timely and cost-effective manner," says Vincent Renz, NewCardio's President and Chief Operating Officer, in a company press release.
By adding this software to its existing offerings, the CRO will also be able to "capture additional" revenue because it will be able to provide customers with more services, the press release reports.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
